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Recommended by Amanda Psyrri
Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice
for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive
role of several biomarkers in an unselected cohort of patients treated with concomitant radiotherapy, weekly cisplatin, and
cetuximab (CCRT). We identiﬁed 37 patients treated with this approach, of which 13 (35%) achieved a complete response and
10 (27%) achieved a partial response. Severe side eﬀects were mainly leucopenia, dysphagia, rash, and anemia. Tumor EGFR,
MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment response. In contrast, high MMP9
mRNA expression was found to be signiﬁcantly associated with objective response. In conclusion, CCRT is feasible and active.
MMP9 was the only biomarker tested that appears to be of predictive value in cetuximab treated patients. However, this is
a hypothesis generating study and the results should not be viewed as deﬁnitive evidence until they are validated in a larger
cohort.
Copyright © 2009 George Fountzilas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.2 Journal of Oncology
1.Introduction
Concomitant chemo-radiotherapy, mainly with cisplatin is
the standard combined modality approach for the treatment
of patients with locally advanced squamous cell carcinoma
of the head and neck (SCCHN) region, because it prolongs
survival and increases the chance of organ preservation com-
pared to radiotherapy (RT) alone [1–3]. Several potential
mechanisms, through which cisplatin acts as a radiosensi-
tizer, have been reported reviewed in [4].
Single-agent cisplatin (100mg/m2) administered every 3
weeks concomitantly with RT is widely used since this high
dose confers a systemic eﬀect and at the same time acts
as a radio-sensitizer [5]. However, the therapeutic beneﬁt
derived from the combined modality is counterbalanced
in many cases by prohibitive toxicity, mainly neurotoxicity,
ototoxicity, emesis, and stomatitis [6] .I no r d e rt or e d u c e
cisplatin-related toxicity, several investigators tested alter-
native schedules of cisplatin administration, such as daily
or weekly infusions. The use of these diﬀerent schedules is
supportedbyinvitrodatashowingthatlowdosesofcisplatin
and RT, when combined, act synergistically in cell killing [3].
During the last few years, investigators within the Hellenic
Cooperative Oncology Group (HeCOG) had adopted the
weekly schedule of cisplatin concomitantly with RT for
the treatment of patients with locally advanced SCCHN
[7].
It is well documented that epidermal growth factor
receptor (EGFR) is overexpressed in 42% to 80% of SCCHN
cases [8, 9]. EGFR plays a pivotal role in proliferation and
survival of SCCHN cells and its overexpression is associated
withadvancedstagesandpoor outcome[10,11]. In previous
studies EGFR expression was proposed as an even stronger
predictor of locoregional control than T stage [9]. For this
reason EGFR appears to be an attractive target of anticancer
drugs. Furthermore, EGFR is an important determinant of
response to RT and confers protection of cancer cells from
the lethal DNA damage induced by ionizing radiation [12–
14].
The main mechanisms through which EGFR confers
radio-protection have recently been reviewed [15]. In vitro
studies suggest that tumors could be sensitized to irra-
diation by blocking the radiation-induced nuclear import
of EGFR, either through the expression of EGFR tyrosine
kinase domain activating mutations or the use of cetuximab
(Erbitux, Merck-Serono). Such mutations however, do not
commonly occur in head and neck cancer.
Cetuximab is an IgG1 monoclonal antibody against the
ligand-binding domain of EGFR. Cetuximab binds EGFR,
sequesters the receptor in the cytoplasm and eventually
targets it for degradation. It has been demonstrated in vitro
that this antibody enhances the radio-sensitivity in SCCHN
cells [16, 17] through several processes reviewed in [18, 19].
Because patients with locally advanced SCCHN recur
locally more often than in distant sites [20, 21], it seems
reasonable for patients with EGFR overexpressing tumors
t or e c e i v em o r ee ﬀective locoregional treatments. One such
treatment strategy is the concomitant administration of RT
with cetuximab. This rationale is supported by preclinical
models,inwhichcetuximabactssynergisticallywithRT[22].
In a pivotal randomized phase III trial [23] the concomitant
administration of cetuximab and RT improved locoregional
control and prolonged survival compared to RT alone in
patients with locally advanced SCCHN.
Following the introduction of cetuximab concomitantly
with RT for the treatment of locally advanced SCCHN, a
number of Greek oncologists used RT with concomitant
administration of cetuximab and weekly cisplatin (herein
named CCRT), as a treatment strategy for such patients.
The background behind this approach was the fact that
cetuximab increased both locoregional control and survival
of such patients. Therefore, it seems logical to add cisplatin
to this active combined therapeutic approach to further
improve outcome, especially since this empirical approach is
supported by in vitro studies [24].
It has been shown in vitro and in tumor specimens
that the expression of the ligand hepatocyte growth factor
(HGF) scatter factor and its receptor HGFR (MET) increase
during invasive growth of SCCHN and this pathway, by
constitutively co-activating other important pathways, may
play a critical role in the metastatic process of SCCHN cells
[25].
The ERCC1 (excision repair cross-complementation
group 1), gene is one of 16 genes encoding for proteins
of the nucleotide excision repair complex, which removes
cisplatin-induced DNA adducts [26]. ERCC1 was shown
in a randomized study [27] to be a signiﬁcant predictive
factor in patients with completely resected non-small-cell
lung cancer (NSCLC) treated with cisplatin-based adjuvant
chemotherapy. In the above study, only patients with ERCC1
negative tumors had shown beneﬁt from the treatment.
Polymorphisms in the 3 -UTR of ERCC1 and in the coding
regions of the ERCC2/XPD and XRCC1 genes have been
associated with disease prognosis and response to cisplatin
in SCCHN patients [28].
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent proteinases that play an important role in the
destruction and repair of the extracellular matrix and
basementmembranesinvariousphysiologicalandpatholog-
ical processes, including gastrointestinal inﬂammation and
carcinogenesis [29, 30]. Importantly, the activation of the
MMPs liberates growth factors from the extracellualr matrix,
including EGFR, FGFR and PDGFR ligands [31]. Preclinical
studies have demonstrated that MMP9 plays an important
role in tumor-induced angiogenesis as well, with tumor-
associated inﬂammatory and stromal cells being the main
source of the proteinase. MMP9-mediated release of vascular
endothelial growth factor (VEGF) and recruitment of per-
icytes to the angiogenic vasculature have been postulated
to be the major processes involved in MMP9-stimulated
angiogenesis [32].
In the present retrospective analysis we report our expe-
riencewiththeuseofCCRTinpatientswithlocallyadvanced
SCCHN. To our knowledge this is the ﬁrst report on the
eﬃcacy of this combination in such patients. Furthermore,
we evaluated the association of a variety of potential tumor
biomarkers with the observed response to CCRT.Journal of Oncology 3
2. Patientsand Methods
2.1. Eligibility and Treatment. The medical records of 37
patients with newly diagnosed, histologically conﬁrmed
locally advanced nonnasopharyngeal SCCHN tumors,
treated with CCRT in four centers, in which the
aforementioned therapeutic strategy was adopted, were
retrospectively reviewed. Patients amenable for this type of
treatment had to have an age of >18 years, performance
status (PS) 0-1 on the Eastern Cooperative Oncology Group
(ECOG) scale and adequate bone marrow, hepatic and renal
function to tolerate treatment. According to our standard
practice, a written informed consent was obtained from
each patient before the acquisition of biological material for
research purposes.
Allpatientsweretreatedwithalinearacceleratorwiththe
intention to receive deﬁnitive RT (70Gy to the tumor area
and 45Gy to the rest of the neck) concomitantly with weekly
cisplatin 40mg/m2 and weekly cetuximab 400mg/m2,a s
a loading dose during the ﬁrst week and 250mg/m2 on
weeks 2–7. Before treatment administration, all patients
were hydrated and given standard premedication. An H3-
antagonist was used as antiemetic in all patients.
Drug doses were modiﬁed according to the grade of
side eﬀects as previously described [7, 33]. Details on the
RT technique, as routinely used in our centers, have been
previously described as well [7]. All adverse events were
graded for this analysis according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version 3.0).
The radiation Therapy Oncology Group (RTOG) criteria
were used to assess RT-related toxicities.
Approximately three months after the completion of
CCRT, all patients underwent a work-up including endo-
scopic examination, chest x-ray, an ultrasound or computer
tomography (CT) scan of the liver, and a CT scan or MRI
of the head and neck region. In selected patients, especially
those with a partial response (PR), an [18F] ﬂuoro-deoxy-
D-glucose (FDG) positron emission tomography (PET)/CT
scan was also recommended. Baseline and post CCRT scans
were retrospectively collected and reviewed by a radiologist
(A. K-F.) experienced in head and neck topology and an
independent radiologist. Response to CCRT was assessed by
the RECIST criteria.
2.2. Tissue Microarray (TMA) Construction. Formalin-ﬁxed
paraﬃn-embedded (FFPE) tumor tissue from 36 patients
was used for protein and gene analysis. Representative
slides (H&E) from the tissue blocks were reviewed by two
experienced pathologists (G. K. and M. B.) for conﬁrmation
of the diagnosis, adequacy of material and calculation of
the percentage of tumor in each case. Thirty-two specimens
were arrayed (2 cores per case, 1.5mm in diameter) into a
recipient paraﬃn block (Paraplast, McCormick, Saint Louis,
MO, USA) using a manual arrayer (Beecher Instruments,
Sun Prairie, WI, USA). The TMA block also included tissue
cores, in the ﬁrst and the last column, from skin, tonsil,
placental, kidney, thyroid, ovarian, prostate, and urothelial
carcinoma that served as positive and negative controls.
2.3. Immunohistochemistry (IHC). Immunohistochemical
labelling was performed according to standard protocols
with slight modiﬁcations [34]o ns e r i a l3μm thick sections,
form the original blocks or the TMA block. As previously
reported [35], the reproducibility of TMA immunostaining
of diﬀerent proteins compared to that obtained from whole
sections of the original paraﬃn blocks is very high. The
deparaﬃnization, antigen retrieval and staining procedures
for EGFR [clone 31G7, Zymed (Invitrogen), Carlsbad, CA,
USA; dilution 1 : 50], ERCC1 (clone 8F11, Neomarkers, Fre-
mont, CA, USA; dilution 1:450), p16INK4A (clone SPM304,
Spring Bioscience, Fremont, CA, USA; dilution 1 : 150),
and p-53 (clone DO-7, Dako, Glostup, Denmark; dilution
1 : 50) were performed using a Bond Max autostainer
(Leica, Wetzlar, Germany). The hepatocyte growth factor
receptor (HGFR/MET) protein was investigated using an
antibody speciﬁc for the external domain of the beta chain of
the MET protein (clone 8F11, Novocastra, Newcastle Upon
T y n e ,U K ) .A f t e rd e p a r a ﬃnization and antigen unmasking,
the slides were incubated for 1 hour at room temperature
with the MET antibody at a dilution of 1 : 50. After
washing the primary antibody, the slides were incubated
with a nonbiotin polymer detection system (BioGenex,
San Ramon, CA) for a total of 40 minutes. The antigen–
antibody complex was visualized using diaminobenzidine
(BioGenex) as a chromogen. Slides were counterstained with
Mayer’shematoxylinfor5min(Leica),washedinfreshwater,
dehydrated, and mounted.
The evaluation of all IHC sections was done simulta-
neously by two pathologists (G. K. and M. B.) blinded as
to the patients’ clinical characteristics and survival data,
according to previously proposed/established criteria with
slight modiﬁcations. EGFR intensity of reactivity was scored
using a four-tier system [36]; 0 (negative), no staining
or background staining; 1+, deﬁnitive cytoplasmic stain-
ing and/or weak discontinuous membranous staining; 2+,
moderate complete or incomplete membranous staining;
3+, strong complete membranous staining. Cases were
considered positive when more than 10% of tumor cells
showedatminimum1+staining,while2+or3+stainingwas
classiﬁed as EGFR protein over-expression.
ERCC1 evaluation of nuclear staining was done accord-
ingtothecriteriaproposedbyOlaussenetal.[27].Theabove
system was based on a semi-quantitative H score, which
combines the stain intensity and the percentage of positive
tumor cells. The median of all H scores was chosen as the cut
oﬀ point for separating positive from negative cases.
HGFR (MET) protein expression was evaluated using
an intensity-adjusted scoring system (combining percentage
and intensity of staining) according to Nakajima et al. [37].
Brieﬂy, intensity scores ranged from 0 to 3 (0 = no staining, 1
= weakly positive, 2 = moderately positive, and 3 = strongly
positive staining), and the staining pattern based on the
percentage of positive tumor cells ranged from 0–3 (0 = 0
to 5%, 1 = 6t o2 5 % ,2= 26% to 50%, and 3 = 51% to
100%). The localization of staining was either cytoplasmic
or cytoplasmic/membraneous. Cases with a total score of
at least 2 were considered positive (expressing tumors),
whereas cases with a total score of 0-1 were grouped together4 Journal of Oncology
and considered to be negative or low expressing tumors.
Nuclear and/or cytoplasmic p16INK4A staining in ≥25% of
tumor cells was considered positive [38]. For p-53 protein
expression, cases were scored as negative or positive, if
≤10% of nuclei or >10% of nuclei were stained, respectively
[39].
2.4. Fluorescence in Situ Hybridization (FISH). FISH was
performed on 4.5μm thick TMA sections or whole sections
of FFPE archival tissue samples using the LSI EGFR/CEP7
Dual Color Probe, (Abbott Molecular, Des Plaines, IL, USA),
theLSID7S486/CEP7DualColorProbe,(AbbottMolecular)
and the speciﬁc for the HGFR/MET gene at region 7q31,
Poseidon Repeat Free MET/SE7 probe (Kreatech Diagnos-
tics, Amsterdam, NL). The EGFR probe, detecting a 300kbp
genomic region spanning the EGFR locus on 7p12, and
the LSI D7S486 detecting a 200kbp genomic region at
region 7q31, were labelled with SpectrumOrange, while
the centromere 7 speciﬁc probe (CEP7) was labelled with
SpectrumGreen. The LSI D7S486/CEP7 Dual Color Probe
was used to identify deletions in 7q31 that have frequently
been detected in SCCHN patients, suggesting the existence
o ft u m o rs u p p r e s s o rg e n e s[ 40]. The HGFR/MET gene
probe was directly labeled with PlatinumBright550 and the
SE7 (Chromosome 7 Satellite enumeration) probe with
PlatinumBright495.
FISH was performed according to the manufacturer’s
protocol with minor modiﬁcations. Brieﬂy, for all probes the
deparaﬃnized tissue sections were incubated in citric acid
solution, pH 6.0 for 10min at 98◦C. After washing twice
for 2min in dH2O, slides were treated with a proteinase K
solution for 10min at 37◦C in a hybridizer (Dako), washed
f o r5 m i ni n2 x S S Cs o l u t i o na n d1m i ni nd H 2O, and
dehydrated (75, 85 and 100% ethanol, each for 1min). Five
to 15μL of the probe mixture were then applied to each
slide, slides were covered by cover slips, sealed with ﬁxogum
rubber cement, heat denatured for 5min at 72◦C( L S I
EGFR/CEP7 and LSI D7S486/CEP7) and 80◦C( M E T / S E 7 )
on a hot plate, and hybridized for at least 16h at 37◦C
in a humidity chamber. After removing the cover slips by
incubation in wash buﬀer (SSC, 0.3% NP-40), slides were
washed for 7min with wash buﬀer at 72◦C. Subsequently,
slides were dehydrated in 70%, 90% and 100% ethanol,
each for 1min, air dried protected from light, and ﬁnally
nuclear counter staining was carried out with DAPI/Antifade
solution (ZytoVision).
In 3 cases, due to inadequate material for the FISH
assays we perform sequential multilocus ﬂuorescence in
situ hybridization (SML-FISH) according to Walch et al.,
with slide modiﬁcations [41]. After image acquisition, the
slides previously hybridized with the LSI D7S486/CEP7 were
washed by heating the section in SSC solution at 75◦Cf o r
16 hours, followed by denaturation at 73◦C for 5 minutes in
70% formamide/SSC. Then, the slides were counterstained
with DAPI and examined under ﬂuorescence (x100 oil lens)
to ensure absence of ﬂuorescent signals. The hybridization,
posthybridization and nuclear counterstaining procedure for
the MET/SE7 probe was performed as mentioned above.
Slides hybridised with the EGFR/CEP7 probe were
analyzed using a Zeiss ﬂuorescence microscope (Axioskop
2 plus HBO 100) equipped with high quality objectives
and an appropriate ﬁlter set. Slides hybridized with the LSI
D7S486/CEP7 and MET/SE7 probes were analyzed using
the Nikon 80i ﬂuorescence microscope (Nikon GmbH,
Dusseldorf, Germany) with a motorized 4 slide stage,
equipped with high quality objectives (all form Nikon), an
appropriate four ﬁlter set [DAPI, doublePath FIRC/TRITC,
ZyGreen that is similar to Abbott Molecular SpectrumGreen
and Kreatech’s PlatinumBright550, and ZyOrange that is
similar to Abbott Molecular SpectrumOrange and Kreatech’s
PlatinumBright495 (all from Chroma Technology Corp,
Rockingham, VT, USA)] and an ultrasensitive black and
white camera (QImaging, Surrey, BC, Canada). As a source
of ﬂuorescence illumination, the X-cite 120 (EXFO Photonic
Solutions Inc, Ontario, Canada) equipped with a long-life
120-watt metal halide short arc lamp was used.
For the assessment of the FISH assays, in the major-
ity of the cases, over 10 ﬁelds (x100) were captured
by a computer-controlled digital camera and processed
by commercially available software systems (FISH Imager
Metasystems, Altlussheim, Germany for EGFR/CEP7 and
XCyto-Gen, Alphelys, Plaisir, France for LSI D7S486/CEP7
and MET/SE7). For the latter probes, sequential, digital
images were captured by a stack motor for the DAPI (1
or 2 planes at 0.5μm), ZyGreen (5 planes at 0.85μmo r4
planes at 1.15μm) and ZyOrange (5 planes at 0.85μmo r4
planes at 1.15μm) ﬁlter settings, and the resulting images
were reconstructed with blue, green and red pseudo-colors.
Sixty nonoverlapping intact nuclei from the invasive part
of the tumor were evaluated for each case according to
morphological criteria using DAPI staining.
The evaluation of the FISH sections was done simul-
taneously by two observers (G. K and M. B). For each
specimen, the absolute and mean copy number per cell
of each DNA probe, the total number and percentage of
cells with zero, one, two, three, and >4 copies of the
respective probe, homozygous and heterozygous deletions,
trisomies and polysomies, as well as the gene/CEP7 ratios
were calculated.
FISH patterns for the EGFR gene were deﬁned as
previously described [42]. The status of the D7S486 locus
was evaluated as follows: deletion if >35% of tumor nuclei
contained one signal; trisomy/polysomy if >10% of tumor
cells showed two or more copies of the D7S486 locus
and chromosome 7. HGFR/MET gene status was classiﬁed
according to Cappuzzo et al. [43] by six FISH strata as
follows: (1) disomy (≤2 copies in >90% of the cells); (2) low
trisomy (≤2 copies in ≥40% of cells, 3 copies in 10–40% of
the cells, ≥4 copies in <10% of cells); (3) high trisomy (≤2
copies in ≥40% of cells, 3 copies in ≥40% of cells, ≥4 copies
in <10% of cells); (4) low polysomy (≥4 copies in 10–40%
of cells); (5) high polysomy (≥4 copies in ≥40% of cells);
and (6) gene ampliﬁcation (deﬁned by the presence of tight
EGFRgeneclustersandaratioofEGFRgenetochromosome
of ≥2o r≥15 copies of EGFR per cell in ≥10% of analyzed
cells).Journal of Oncology 5
2.5. EGFR, ERCC1 and MMP9 mRNA Expression. For this
retrospective study, intact RNA of high quality, as deter-
mined by analysis of the housekeeping gene RPL37A, was
isolated from 33 FFPE tumour tissue samples employing an
experimental method based on proprietary magnetic beads
from Siemens Healthcare Diagnostics (Cologne, Germany),
as previously described [44]. The number of malignant
cells represented at least 30% of all nucleated cells per
section, as veriﬁed by hematoxylin-eosin staining. Kinetic
reverse transcription-polymerase chain reaction (kRT-PCR)
was applied for the assessment of messenger RNA (mRNA)
expression of EGFR, ERCC1 and MMP9 using the following
TaqMan based primer/probe sets:
EGFR Probe CCTTGCCGCAAAGTGTGTAAC-
GGAAT
Forward Primer CGCAAGTGTAAGAAGTGC-
GAA
Reverse Primer CGTAGCATTTATGGAGAG-
TGAGTCT
ERCC1 Probe TCCTCGCCTGGAGCCCCGA
Forward Primer AGGAGCTGGCTAAGATGT-
GTATCCT
Reverse Primer CCAGGTACCGCCCAGCTT
MMP9 Probe CAGGCAGCTGGCAGAGGAATA-
CCTGTAC
Forward Primer CCCTGGAGACCTGAGAAC-
CA
Reverse Primer CCACCCGAGTGTAACCAT-
AGC
RPL37A and GAPDH were used as housekeeping (nor-
malization) genes. Forty cycles of nucleic acid ampliﬁcation
were applied and the cycle threshold (CT) values of the
target genes were identiﬁed. CT values were normalized by
subtracting the CT value of the housekeeping gene RPL37A
from the CT value of the target gene (ΔCT). RNA results
were then reported as 40-ΔCT values, which correlated
proportionally to the mRNA expression level of the target
gene.
Human reference total RNA pooled from ten human cell
lines (Stratagene, La Jolla, CA) was used as a positive control.
RNA-free DNA extracted from tumor tissues was used as a
negative control.
2.6. ERCC1, ERCC2/XPD and XRCC1 Gene Polymorphisms.
DNA from peripheral blood and FFPE tissues was normal-
ized at 20ng/uL. The following Taqman SNP genotyping
assays were used [Applied Biosystems, Biosolutions, Athens,
GR]: C 3145050 10, detecting the ERCC2 Asn312Asp
(AAC/GAC) polymorphism [rs1799793]; C 3145033 10,
detecting the ERCC2 Lys751Gln (AAG/CAG) polymorphism
[rs13181]); C 622564 10, detecting the XRCC1 Gln399Arg
(CAG/CGG) polymorphism [rs25487]; and C 2532948 10,
detecting the ERCC1 C8092A/CD3EAP Q504K (Gln/Lys)
polymorphism [rs3212986]. Of note, the sequence
detected by this assay (CACAGGCCGGGACAAGAAGCG-
GAAG[C/A]AGCAGCAGCAGCAGCCTGTGTAGTC),
which matches previous reports [45], includes a
polymorphism in the 3 -UTR of the ERCC1 gene, which is
simultaneously located at the 3 end of the CD3EAP coding
region (http://www.ncbi.nlm.nih.gov/SNP/snp ref.cgi?rs=
3212986), since these genes are located in opposite
directions at 19q13.3. Thus, CTG>C T T( G / Tc h a n g e )
is the forward sequence in ERCC1, corresponding to
the reverse CAG>AAG (C/A change) in CD3EAP. Runs
w e r ep e r f o r m e di nd u p l i c a t e si n1 0 μL reactions with
40ng DNA input, ampliﬁed for 40 cycles under standard
conditions in an ABI7500 real time PCR system equipped
with the SDS v1.4 software keeping the default parameters
(Applied Biosystems, Biosolutions, Athens, GR). Negative
control did not provide ampliﬁcation curves, while sample
ampliﬁcation curves were considered for further analysis
if the cycle threshold (Ct) for the detected products was
<38. Diﬀerences of the mean Cts (dCt) for the two alleles
detected by each assay were: −1.93 for ERCC1 C8092A, 0.47
for ERCC2 N312D, 1.55 for ERCC2 K751Q, and 1.34 for
XRCC1 Q399R, all within the acceptable limits for this type
of assays (±2) (Applied Biosystems).
2.7. EGFR and kRAS Mutation Analysis. Genomic DNA was
derived from FFPE tumors as previously described [45].
Samples consisting of >75% tumor cells were considered as
eligible for DNA extraction and sequence analysis, otherwise
macrodissection was performed to increase the tumor cell
content to >75%.
We ampliﬁed exons 18, 19, 20, and 21 of the EGFR
tyrosine kinase domain from genomic DNA (primary tumor
tissue DNA) and germline DNA (peripheral blood DNA)
that was extracted with the Invisorb Spin Blood Midi
Kit (Invitek GmbH, Berlin, Germany) according to the
manufacturers instructions. All PCR’s were conducted as
previously described [46]. All mutations were reconﬁrmed
by PCR ampliﬁcation and analysis of an independent DNA
isolate. Exons 18, 19, 20, and 21 were reconﬁrmed in all
patients identiﬁed as harboring mutations. Germline DNA
was analyzed on two separate occasions for exons 18, 19, 20,
and 21 for all patients with mutations, in order to conﬁrm
EGFR mutations as somatic or germline in origin. kRAS
mutation analysis of codons 12 and 13 was performed as
previously described [47].
All PCR products were puriﬁed by solid-phase reversible
immobilization chemistry followed by bi-directional dye-
terminator ﬂuorescent sequencing. All exons were sequenced
with the inner forward and reverse primers used for PCR.
Sequences were analyzed by BLAST and chromatograms by
manual review, and compared to: EGFR mRNA reference
sequence Accession number NM 005228 and/or the EGFR
gene sequence Accession number AF288738; RAS mRNA
GI 34485723 and/or the RAS gene sequence GI 14277199
(http://www.ncbi.nlm.nci/).6 Journal of Oncology
The EGFR exon 21 mutation, L858R, was also analyzed
by PCR/RFLP based on the presence of a new Sau96I
restriction site created by the mutation. Deletions in exon
19 were also analyzed for using high performance gel
electrophoresis (>2.5% agarose).
2.8. HPV Detection. Detection of HPV-16 and HPV-18
DNA was performed by one of the authors (A. L.)
and was based on ampliﬁcation of the E6 region as
adopted from Ogura et al. [48], with minor modiﬁca-
tions. Brieﬂy, each reaction contained 0.2–0.4μgD N A
t e m p l a t ei n1 0 m MT r i s ,p H8 . 3 ,5 0 m MK C l ,1 . 5 m M
MgCl2, 200mM dNTPs, 1.5 units Taq DNA polymerase
(Fermentas), and 100pM of each of the primers in a total
volume of 50μL. Sense and antisense primer sequences
f o rH P V - 1 6E 6w e r e5  -AAGGGCGTAACCGAAATCGGT-
3  and 5 -GTTTGCAGCTCTGTGCATA-3 ,r e s p e c t i v e l y .
The same sense primer was used for HPV-18 E6.
The antisense primer sequence for HPV-18 E6 was 5 -
GTGTTCAGTTCCGTGCACA-3 .
The reaction mixure was subjected to PCR ampliﬁcation
using the GeneAmp PCR system 9700 thermal cycler (ABI).
PCR cycling conditions consisted of 7 min at 96◦C and 1 min
at 72◦C, followed by 35 cycles, including a denaturation step
at 94◦C for 30s, an annealing step at 55◦Cf o r3 0sa n da n
elongation step at 72◦C for 45s. The ﬁnal extension step was
c a r r i e do u ta t7 2 ◦C. To avoid false positive and/or negative
results a control (no template DNA) and an HPV positive
DNA sample were included.
2.9. Statistical Analysis. Data on selected patient or tumor
characteristics, and acute toxicity were obtained from the
records. Responses were summarized as number of patients
and corresponding percentages. Comparisons of the number
ofrespondersaccordingtobiomarkerswereperformedusing
the Fisher’s exact test.
Overall survival (OS) was measured from treatment
initiation to patient’s death or last contact. Progression-free
survival (PFS) was measured from treatment initiation to
veriﬁed disease progression, death or last contact. In the
analysis of PFS, death without prior veriﬁed progression
was encountered as event. OS and PFS were estimated by
the Kaplan-Meier method. For all comparisons, level of
signiﬁcance was set at a = 0.05.
3. Results
3.1. Patients’ Compliance and Toxicity. Totally, 37 patients
fulﬁlling the eligibility criteria were included in this retro-
spective analysis. There were 27 men and 10 women with a
median age of 60 years (Table 1). Thirty-ﬁve patients (95%)
completed CCRT. One patient discontinued CCRT after the
completion of the 6th week of treatment due to grade 3
thrombocytopenia. One patient, a 74-year-old man, with
a history of angina and atrial ﬁbrillation died from acute
myocardial infarction during the second week of RT. In
the process of reviewing the clinical data, 5 more patients
were identiﬁed to have had fatal events during the 3-month
Table 1: Patient characteristics (N = 37).
Age
Median 59
Range 36–82
N %
Gender
Men 27 73
Women 10 27
Performance status
03 3 8 9
13 8
21 3
Primary site
Oral cavity 12 32
Larynx 11 30
Oropharynx 8 22
Hypopharynx 4 11
Paranasal Sinuses 1 3
Major Salivary Glands 1 3
Stage
II 2 5
III 6 16
IV 29 78
period post CCRT. More analytically, one of the patients
from progressive disease, while a second patient, a 60-year-
old man with an unremarkable medical history, from cardiac
arrest, one week after the completion of CCRT. Autopsy was
refused by his relatives. A third patient, a 46-year-old man,
died from massive haemorrhage of the upper aerodigestive
truck, 11 weeks post CCRT. Autopsy suggested that the fatal
event was attributed to bleeding from a mucosal ulceration
on the right pyriform sinus. No evidence of tumor was
found. The latter patient, even though a post CCRT scan was
not performed, was considered in the present analysis to be
complete responder. The fourth patient, a 60-year-old man,
alcoholic and heavy smoker, was at the initiation of CCRT
on treatment for pulmonary tuberculosis with isoniazid and
rifambicin. He died 7 weeks post CCRT. Further medical
information about the cause of death could not be obtained.
The ﬁfth patient, a 56-year old man with alcoholic cirrhosis
died 12 weeks post CCRT from massive bleeding due to
the rupture of esopharyngeal varices. The above patients
were included in the analysis for response on an “intent to
treat” basis. Severe side eﬀects most commonly noticed were
leukopenia (70%), dysphagia (62%), skin rash (65%), and
anemia (51%) (Table 2).
3.2. Response to CCRT and Survival. Following the com-
pletion of CCRT, response was evaluated according to the
RECIST criteria for 24 out of 37 patients (Figure 1). For
6 of these patients response was evaluated by PET as well.
For one of the patients, response was classiﬁed as partial by
RECIST, while PET was free of tumor, thus this patient was
consideredtobeacompleteresponderintheoverallresponseJournal of Oncology 7
Table 2: Worst toxicity expressed as N (%) during CCRT (RTOG criteria).
Grade 1 Grade 2 Grade 3 Grade 4
Anemia 12 (32) 6 (16) 1 (3) 0 (0)
Neutropenia 3 (8) 13 (35) 7 (19) 0 (0)
Leucopenia 4 (11) 11 (30) 11 (30) 0 (0)
Thrombocytopenia 4 (11) 3 (8) 2 (5) 0 (0)
Nausea/vomiting 11 (30) 5 (14) 1 (3) 0 (0)
Fatigue 5 (14) 9 (24) 3 (8) 0 (0)
Dysphagia/anorexia 2 (5) 14 (38) 7 (19) 0 (0)
Weight Loss 2 (5) 2 (5) 1 (3) 0 (0)
Dermatitis 3 (8) 7 (19) 2 (5) 0 (0)
Rash 8 (22) 12 (32) 3 (8) 1 (3)
Mucositis 9 (24) 9 (24) 5 (14) 0 (0)
Mouth dryness 6 (16) 7 (19) 0 (0) 0 (0)
Constipation 10 (27) 1 (3) 1 (3) 0 (0)
Diarrhea 0 (0) 1 (3) 1 (3) 0 (0)
Infection 2 (5) 0 (0) 1 (3) 0 (0)
HSR 4 (11) 2 (5) 0 (0) 0 (0)
Otitis 0 (0) 3 (8) 0 (0) 0 (0)
Hoarseness 3 (8) 4 (11) 1 (3) 0 (0)
Peripheral Neuropathy 0 (0) 1 (3) 0 (0) 0 (0)
Nephrotoxicity 0 (0) 1 (3) 0 (0) 0 (0)
Confusion 1 (3) 0 (0) 0 (0) 0 (0)
Dizziness 3 (8) 0 (0) 0 (0) 0 (0)
Pruritus 2 (5) 0 (0) 0 (0) 0 (0)
Bleeding 3 (8) 0 (0) 0 (0) 0 (0)
Pain 1 (3) 1 (3) 0 (0) 0 (0)
Dry skin 1 (3) 0 (0) 0 (0) 0 (0)
Memory loss 1 (3) 0 (0) 0 (0) 0 (0)
Seizure 1 (3) 0 (0) 0 (0) 0 (0)
evaluation. In one additional case, response was evaluated by
PET only.
Of the remaining 12 non-evaluable patients, one did not
have a CT examination, for 5 patients the CT examinations
were not available for central review, while 6 patients died
before their response evaluation. However, for one of the
latter patients an autopsy was performed and no evidence of
tumor was found. This patient is considered to be a complete
responder.
Overall, 11 patients (30%, 95% CI 16%–47%) achieved
a CR and 11 (30%, 95% CI 16%–47%) a PR. Stable
disease was seen in 3 patients (8%, 95% CI 2%–22%) and
progressive disease in 5 patients (14%, 95% CI 5%–29%).
For one patient the CT examination was not available, and
therefore was not evaluated for response. Notably, among
three patients with radiological PR that underwent an FDG-
PET/CT, one of them had a negative examination. Therefore,
this patient was considered as a complete responder in the
ﬁnal analysis. Taking into account the one patient with
no evidence of tumor in the autopsy, 13 patients were
considered as having achieved a CR (35%, 95% CI 8%–
52%) and 10 as having achieved a PR (27%, 95% CI 14%–
44%).
Afteramedianfollow-upof21.3months,15patientshad
a PFS event (10 patients demonstrated disease progression
and 5 died of other causes), while a total of 9 patients had
died.One-yearprogression-freeandoverallsurvivalwas63%
and 80%, respectively.
3.3. Immunochemistry and FISH. Individual EGFR, ERCC1,
MET, p16INK4A, and p-53 IHC and FISH data along with
selected patient characteristics and responses are presented
in Tables 3 and 4. In summary, thirty-one of 32 tumor
samples (97%) were found to be EGFR positive, while in
22 samples (69%) EGFR was overexpressed (Figures 2(a)
and 2(b)). No association between EGFR overexpression and
complete response was identiﬁed (9/22 CRs among patients
with EGFR overexpression versus 2/10 CRs among patients
without EGFR overexpression; P = .425). One sample was
EGFR ampliﬁed (Figures 3(a) and 3(b)).
The ERCC1 protein was expressed (Figures 2(c) and
2(d)) in 27 out of 33 tumor samples (82%). No associa-
tion between ERCC1 expression and response was found
(9/27 responders among ERCC1 positive patients versus 2/6
responders among ERCC1 negative patients; P = .999).8 Journal of Oncology
Table 3: Selected patient and tumor characteristics, EGFR, MET, p-53, HPV-16, and p16 status and response to CCRT.
n Primary site Gender Age Response EGFR EGFR EGFR MET MET MET p-53 HPV-16 p16
(years) (IHC) (FISH) (mRNA) (IHC) (FISH) (FISH) (IHC) (DNA) (IHC)
(1) Oral cavity W 69 PR 2+ LLG H N TR GAIN 5 N N
(2) Oral cavity M 66 PR 2+ DI H P TR GAIN >90 N N
(3) Oral cavity M 59 PR 2+ TR H N TR GAIN >90 N N
(4) Oral cavity M 82 CR 3+ DI H N LP GAIN >90 P N
(5) Oral cavity M 61 NE 3+ TR L P LP GAIN >90 P N
(6) Oral cavity M 69 PD 1+ DI L N DI NORMAL >90 — —
(7) Oral cavity W 41 PD 3+ DI L P TR GAIN 80 — N
(8) Oral cavity W 60 CR 3+ TR H P TR GAIN 0 N N
(9) Oral cavity M 44 CR 3+ TR H P TR GAIN 30–40 P P
(10) Oral cavity M 60 ED 2+ DI L P TR GAIN >90 N P
(11) Oral cavity W 59 PD 3+ DI H P LP GAIN 20–30 N N
(12) Oral cavity W 55 CR — — Undet. — — — — — —
(13) Oropharynx M 57 CR 3+ AMPL H P LP GAIN >90 N N
(14) Oropharynx W 36 CR 2+ DI L N LP GAIN <5P P
(15) Oropharynx M 59 CR 3+ DI L N LP GAIN 0 N N
(16) Oropharynx W 55 CR 3+ DI L P LP GAIN 30–40 P P
(17) Oropharynx M 69 PR 3+ DI Undet. N DI NORMAL — — P
(18) Oropharynx M 46 CR NE — H — — — — N P
(19) Oropharynx M 73 PD 1+ TR H N TR GAIN 0 N N
(20) Oropharynx M 67 SD 3+ TR H P DI NORMAL 70–80 N N
(21) Hypopharynx M 46 ED 3+ TR H N HP GAIN >90 N —
(22) Hypopharynx W 64 PR NE — L — — — N —
(23) Hypopharynx M 56 ED 3+ TR L P DI NORMAL >90 P N
(24) Hypopharynx W 56 PR 3+ DI L N — — 0 — —
(25) Larynx M 55 CR 3+ DI H N DI NORMAL 0 N N
(26) Larynx M 68 PR 2+ DI L N TR GAIN >90 N N
(27) Larynx M 60 ED — — Undet. — — — — — —
(28) Larynx M 42 PR 3+ DI L N DI NORMAL >90 N N
(29) Larynx M 76 CR 3+ LLG L N DI NORMAL 30–40 N N
(30) Larynx M 74 ED NE DI L N — — 0 N —
(31) Larynx W 46 SD 3+ DI L P TR GAIN 5–10 N P
(32) Larynx M 74 ED 2+ DI L P TR GAIN >90 N P
(33) Larynx M 67 PD 3+ LLG H N TR GAIN >90 N N
(34) Larynx M 54 CR 2+ DI H N TR GAIN 0 N N
(35) Larynx M 54 PR 3+ DI Undet. N DI NORMAL — — N
(36) Paranasal Sinuses M 65 SD 3+ LLG H P TR GAIN >90 N N
(37) Major Salivary Gland M 74 PR 3+ TR L N LP GAIN >90 N N
n = sample order number, M = man, W = woman.
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = nonevaluable, ED = early death.
LLG = low level gain, DI = disomy, HP = high polysomy, LP=low polysomy, TR = trisomy, AMPL = ampliﬁcation.
P = positive, N = negative, H = high, L = low, Undet. = undetermined by real time PCR.
The MET protein was expressed (Figures 2(e) and 2(f))
in 14 out of 33 tumor samples (42%). The MET protein
was detected as membraneous discontinuous or complete
staining and/or cytoplasmic staining. In a small number
of cases the endothelial cells of stromal vessels showed
mild to moderate staining. No association between MET
protein expression and complete response was found (4/14
complete responders among MET positive patients versus
7/19 complete responders among MET negative patients;
P = .719). However, when considering objective response
(CRorPR),asigniﬁcantassociationwasidentiﬁedwithMET
protein expression (5/14 responders among MET positive
patientsand15/19respondersamongMETnegativepatients;
P = .029).
MET gene gain was observed in 23 of 31 cases (74%).
More speciﬁcally, low trisomy was detected in 16 cases, low
polysomy in 6 cases, while high polysomy was identiﬁed in
1 case (Figures 3(c) and 3(d)). MET gene status was notJournal of Oncology 9
Table 4: Selected patient and tumor characteristics and response to CCRT in comparison to excision repair genes and MMP9 status.
ERCC1 ERCC1 ERCC1 C8092A/ ERCC2- ERCC2- XRCC1- MMP9
n Primary site Gender Age Response (IHC) (mRNA) CD3EAP Q504K# 312# 751# 399# (mRNA)
(1) Oral Cavity W 69 PR N H A/A Asn/Asp Gln/Lys Arg/Arg H
(2) Oral Cavity M 66 PR P H C/C Asp/Asp Lys/Lys Arg/Arg H
(3) Oral Cavity M 59 PR P L C/C Asp/Asp Lys/Lys Arg/Arg H
(4) Oral Cavity M 82 CR P H C/C Asp/Asp Lys/Lys Gln/Arg H
(5) Oral Cavity M 61 NE P L A/C Asp/Asp∧ Gln/Lys Gln/Arg L
(6) Oral Cavity M 69 PD P L A/C∗ Asn/Asn∗ Gln/Gln∗ Gln/Gln∗ L
(7) Oral Cavity W 41 PD P L A/C∗ Asn/Asp∗ Gln/Lys∗ Gln/Arg∗ L
(8) Oral Cavity W 60 CR P H C/C Asp/Asp Lys/Lys Gln/Arg H
(9) Oral Cavity M 44 CR P H C/C Asn/Asn Gln/Gln Arg/Arg H
(10) Oral Cavity M 60 ED P L C/C undet. undet. undet. L
(11) Oral Cavity W 59 PD P L A/C Asn/Asp Gln/Lys Arg/Arg H
(12) Oral Cavity W 55 CR Undet. Undet. A/C Asp/Asp Lys/Lys Gln/Arg Undet.
(13) Oropharynx M 57 CR P H C/C undet. undet. undet. H
(14) Oropharynx W 36 CR P L C/C Asn/Asp Gln/Gln Gln/Arg H
(15) Oropharynx M 59 CR P L A/C Asn/Asp Gln/Lys Gln/Arg L
(16) Oropharynx W 55 CR N H A/C Asn/Asp Gln/Lys Arg/Arg H
(17) Oropharynx M 69 PR P Undet. A/C Asn/Asn Gln/Lys Gln/Arg Undet.
(18) Oropharynx M 46 CR N L C/C Asn/Asp Gln/Lys Arg/Arg L
(19) Oropharynx M 73 PD P L C/C Asp/Asp∧ Gln/Lys Gln/Gln L
(20) Oropharynx M 67 SD P H A/A Asn/Asn Gln/Gln Gln/Arg L
(21) Hypopharynx M 46 CR P H A/C Asn/Asp Gln/Lys Gln/Arg H
(22) Hypopharynx W 64 PR N H C/C Asp/Asp Lys/Lys Arg/Arg L
(23) Hypopharynx M 56 ED P L A/C Asn/Asp∧ Lys/Lys Gln/Arg L
(24) Hypopharynx W 56 PR P L C/C∗ Asn/Asp∗ Gln/Lys∗ Gln/Arg∗ H
(25) Larynx M 55 CR N H A/C Asn/Asp Gln/Lys Gln/Arg H
(26) Larynx M 68 PR N L A/A Asp/Asp Lys/Lys Arg/Arg L
(27) Larynx M 60 ED — Undet. — — — — Undet.
(28) Larynx M 42 PR P N C/C Asn/Asn Gln/Lys Gln/Gln H
(29) Larynx M 76 CR P H A/C Asn/Asp Gln/Gln Gln/Arg L
(30) Larynx M 74 ED P N C/C Asn/Asp Gln/Lys Arg/Arg L
(31) Larynx W 46 SD P N A/C Asn/Asp Gln/Lys Gln/Arg L
(32) Larynx M 74 ED N H A/A
∧ Asn/Asp Lys/Lys Gln/Arg L
(33) Larynx M 67 PD N H C/C Asp/Asp Lys/Lys Arg/Arg L
(34) Larynx M 54 CR P N C/C Asp/Asp Lys/Lys Arg/Arg L
(35) Larynx M 54 PR P Undet. A/C Asn/Asp Gln/Lys Gln/Arg Undet.
(36) Paranasal Sinuses M 65 SD P H C/C Asp/Asp Gln/Lys Gln/Arg H
(37) Major Salivary Glands M 74 PR P H C/C Asp/Asp Gln/Lys Gln/Arg H
n = sample order number; M = man; W = woman; H = high; L = low; P = positive; N = negative; # = genotypes from tumor tissue or from matched peripheral
bloodand tumortissue samples, unless otherwise speciﬁed; ∧ = mismatchedtumor/peripheral bloodgenotypes(tumordataare shown); ∗ = peripheralblood
data only; Undet. = undetermined by real time PCR.
found to be associated with response (2 responders among
8 patients with normal MET gene status versus 9 responders
among 23 patients with MET gene gain, P = .676).
The p16INK4A protein was detected in 8 out of 30
cases examined (27%). In addition, in 5 of the 22 negative
cases, p16 was highly expressed in the dysplastic squamous
epithelium. Two of them showed p16 expression mainly
in the dysplastic epithelium and to a small degree in
scattered inﬁltrative neoplastic cells. No association was
found between p16 and HPV-16 (P = .290). Furthermore,
p16 was not found to be associated with response (4
responders among 8 patients with positive p16 status versus
7 responders among 22 patients with negative p16 status,
P = .417).
The p-53 protein was found to be expressed (Figures
2(g) and 2(h)) in 22 of 33 patients (67%). No signiﬁcant
association with complete response was identiﬁed (6/22
complete responders among p-53 positive patients versus10 Journal of Oncology
Table 5: Incidence of excision repair genotypes in head and neck cancer patients. Peripheral blood (PB) and tumor tissue (TT) data.
ERCC1 C8092A/
CD3EAP Q504K ERCC2-312 Asn/Asp ERCC2-751 Lys/Gln XRCC1-399 Gln/Arg
(CAG/AAG) (AAC/GAC) (AAG/CAG) (CAG/CGG)
PB (n = 26) C/C 12 (46.2%) (G/G) Asp/Asp 8 (30.8%) (C/C) Gln/Gln 4 (15.4%) (G/G) Arg/Arg 8 (30.8%)
A/C 13 (50%) (A/G) Asn/Asp 13 (50%) (A/C) Lys/Gln 15 (57.7%) (A/G) Gln/Arg 15 (57.7%)
A/A 1 (3.8%) (A/A) Asn/Asn 5 (19.2%) (A/A) Lys/Lys 7 (26.9%) (A/A) Gln/Gln 3 (11.5%)
TT (n = 33) C/C 17 (51.5%) (G/G) Asp/Asp 12 (38.7%) (C/C) Gln/Gln 5 (16.1%) (G/G) Arg/Arg 12 (38.7%)
A/C 12 (36.4%) (A/G) Asn/Asp 15 (48.4%) (A/C) Lys/Gln 16 (51.6%) (A/G) Gln/Arg 16 (51.6%)
A/A 4 (12.1%) (A/A) Asn/Asn 4 (12.9%) (A/A) Lys/Lys 10 (32.3%) (A/A) Gln/Gln 3 (9.7%)
Undet. 0 2 2 2
Undet. = undetermined with real time PCR.
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Figure 1: Waterfall for the response of target lesions according to
RECIST criteria (N = 24).
5/11 complete responders among p-53 negative patients; P =
.437).
Moreover, no signiﬁcant association between the status
oftheD7S486locus(Figures3(e)and3(f))andresponsewas
identiﬁed.
3.4. EGFR, ERCC1, and MMP9 mRNA Expression. Indi-
vidual EGFR, ERCC1 and MMP9 mRNA data along with
selected patient characteristics and responses are presented
in Tables 3 and 4. For all three genes the median was used
as a pre-deﬁned cut-oﬀ in order to classify tumors with
high (above the median) or low (below the median) mRNA
expression.ThemediannormalizedEGFRmRNAexpression
was 34.9 (29.6–39.5). High EGFR mRNA expression, was
not found to be associated with complete response (4/17
complete responders among patients with low EGFR mRNA
expression, versus 8/16 complete responders among patients
with high EGFR mRNA expression; P = .157).
Similarly, the median normalized ERCC1 mRNA expres-
sion was 34.8 (30.0–39.5), while no association between
high ERCC1 mRNA expression and complete response was
identiﬁed. Speciﬁcally, in the group of 17 patients with low
ERCC1 mRNA expression 4 patients achieved a complete
response, versus 8 complete responders among the 16
patients with high ERCC1 mRNA expression (P = .157).
Finally, the median normalized MMP9 mRNA expres-
sion was 34.3 (29.5–39.5). Only 4 of the 17 patients with
low MMP9 mRNA expression achieved a complete response,
while8ofthe16patientswithhighMMP9mRNAexpression
demonstrated a complete response to treatment (P = .157).
Although MMP9 mRNA expression was not found to be
signiﬁcantly associated with complete response, a signiﬁcant
association with the objective response (CR or PR) was
identiﬁed (6/17 responders among patients with low MMP9
mRNA expression versus 14/16 responders among patients
with high MMP9 mRNA expression, P = .004).
3.5. ERCC1, ERCC2/XPD, and XRCC1 Gene Polymorphisms.
Samples from 36 patients were considered for allelotyping,
including10fromtumortissueonly,3fromperipheralblood
(germline) only and 23 from matched peripheral blood
and tumor tissue. The incidence of allelic combinations
in germline and tumor tissues is shown in Table 5, while
individual data on ERCC1, ERCC2 and XRCC1 gene poly-
morphisms are presented in Table 4. Brieﬂy, heterozygous
polymorphic alleles were common for all targets; con-
cerning homozygous combinations, C8092C was the most
frequent genotype for ERCC1, Asp312Asp and Lys751Lys for
ERCC2/XPD and Arg399Arg for XRCC1. In 2/10 unmatched
tumor tissue samples, allelotyping data could be obtained
for ERCC1 but not for ERCC2 and XRCC1, probably due
to poor FFPE DNA quality. Overall, the incidence of allelic
variantsobservedinthepresentstudywasinaccordancewith
relevant previous data [28].
The germline genotype did not always match the tumor
genotype in the same patient, as deduced from the high dCts
(5.8, 7.3, and 7.9 in three cases) in the respective tumorJournal of Oncology 11
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(e) (f) (g) (h)
Figure 2: Immunohistochemistry performed on tissue microarrays. (a) EGFR protein expression in all tumor cells with focal intense
complete membranous staining (+3); (b) EGFR negative case showing mild cytoplasmic focal staining; (c) ERCC1 protein strong nuclear
positivity; (d) ERCC1 protein expression with equal intensity in neoplastic cells and stromal ﬁbroblasts (regarded as negative staining); (e)
MET strong cytoplasmic and membraneous protein expression; (f) Lack of MET protein expression in tumor cells; (g) p-53 strong nuclear
protein expression; (h) p-53 expression in a small fraction of tumor cells (regarded as negative staining). Original magniﬁcation x20; insets
(a), (c), and (g) x200; insets (b), (d), (e), and (h) x400.
samples or from the ampliﬁcation of allele targets that were
negative in the matching peripheral blood samples. Changes
in tumor genotypes were observed upon repeated testing
in 4/23 patients (17%) with matched peripheral blood and
tumor samples available for comparison (Table 4). Germline
heterozygocity was replaced in one case by homozygocity
for the rare A/A allele for ERCC1 C8092A/CD3EAP Q504K,
indicating a Lys/Lys genotype for CD3EAP in the tumor.
In two additional cases, germline A/G was replaced by G/G
for ERCC2-312 (change of Asn/Asp into Asp/Asp in the
tumor). In another case, germline ERCC2-312 Asp/Asp (no
ampliﬁcation of the Asn target) was replaced by Asn/Asp
(dCt = 1.1) in the matched tumor tissue.
3.6. Mutational Analysis. Only one patient had a somatic
EGFR mutation on exon 20, a D770insGF insertion. No
patients were found with a kRAS codon 12/13 mutation.
Additionally, no patients were identiﬁed with an L858R
EGFRmutationorcodon19deletionbyalternativemethods.
3.7. HPV Detection. We examined the presence of HPV-16
and 18 E6 in 30 patients by PCR. Totally, 6 out of 30 samples
(20%) tested were HPV-16 positive (one laryngeal, 3 oral
cavity and 2 oropharyngeal tumors). All samples proved to
be HPV-18 negative. Interestingly, 4 of the 6 HPV-16 positive
patients, who were evaluable for response, achieved a CR
post CCRT.
4. Discussion
The present report describes our collective experience with
CCRT in patients with locally advanced SCCHN. The CR
rate achieved in such a heterogeneous group of patients
was 35%. Additionally, 10 patients (27%) were considered
as having a PR. Interestingly, one patient with a PR had
a negative FDG-PET/CT after the completion of CCRT
and was considered as having a CR. It is well known that
assessment of response to chemo-radiotherapy in patients
with SCCHN is not accurate, since a number of them are
consideredbyradiologistsashavingpartialresponse,because
of residual abnormalities in posttreatment CT scans. During
the last few years FDG PET/CT scans had been increasingly
used for initial staging and assessment of tumor response in
SCCHN [49]. Several investigators have shown that FDG-
PET/CT can more accurately predict the lack of residual
disease both at the primary site and the neck (negative
predictive value 100%, sensitivity 100% and speciﬁcity 96%)
[50, 51] and it has therefore been considered to be a valuable
clinical tool in the management of SCCHN.
The review of our clinical data showed that the treatment
was feasible and that the compliance of the patients was
satisfactory, since all except two completed RT. It is well
known that most patients with SCCHN belong to low social-
economic status, are alcoholic, heavy smokers, and bear
serious co-morbidities. Furthermore, serious toxic sequelae
of chemo-radiotherapy, such as dehydration, infections,12 Journal of Oncology
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Figure 3: Fluorescence in situ hybridization with gene and
centromeric speciﬁc probes. (a) and (b) Neoplastic nuclei showing
polysomy of chromosome 7 (CEP7, green signals) and EGFR high
level gene gain (red signals, arrowheads); (c) Neoplastic nuclei
showing trisomy or polysomy of the MET gene (red signals) and
SE7 (green signals); (d) Representative area from a case without
genetic alterations. The majority of the neoplastic nuclei have 2
copies of the MET gene and SE7; (e) High polysomy of the D7S486
locus (red signals); (f) Deletion of the D7S486 gene locus in tumor
cells, as deﬁned by the presence of a single gene locus probe
signal (red signals) and two CEP7 signals (green signals), or by the
simultaneous lack of both of the gene locus signals and the presence
of CEP7 signals (hemizygous and homozygous deletion, resp.).
malnutrition, and excessive weight loss may deteriorate their
general heath status and contribute to fatal events. A high
incidence of unexpected severe adverse events, including
fatal events, was described by Pﬁster et al. [52]i na
phase II study and was conﬁrmed in our retrospective
analysis of an unselected SCCHN population. These patients
should therefore be closely monitored during CCRT and the
immediate period following CCRT.
The discovery of predictive factors in treatments, such
as RT concomitantly with cetuximab, is of paramount
importance, since this regimen is emerging as the new stan-
dard for patients with SCCHN. Unfortunately, to date the
identiﬁcation of such molecular predictors remains elusive.
In the present analysis, we evaluated potential associations of
EGFR, MET, ERCC1, and MMP9 with response to CCRT.
Even though high EGFR protein expression has been
reported to be predictive for increased tumor response in
patients with SCCHN treated with conventional fractionated
[9] or accelerated [53, 54] RT, this ﬁnding has not been
conﬁrmed in randomized studies in patients with recurrent
and/or metastatic SCCHN treated with geﬁtinib [55]o r
cisplatin and cetuximab [56]. Contrary to what would be
expected, patients with low to moderate EGFR protein
expression demonstrated a higher response rate to the
combinationofcisplatinandcetuximabthanthosewithhigh
EGFR expression. In our retrospective analysis, we were not
able to ﬁnd a correlation between EGFR protein expression
and response to CCRT.
We have also assessed EGFR gene copy number by FISH.
We found that in most of the tumors EGFR polysomy but
not ampliﬁcation was evident; however, it was not correlated
with response. These ﬁndings are in agreement with other
trials, showing that the prevalence of EGFR ampliﬁcation in
SCCHN is low [57, 58] and that EGFR gene copy numbers
are not correlated with tumor response in patients with
recurrent/metastatic SCCHN, who nevertheless responded
to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib or
geﬁtinib [59, 60]. It has been reported that in nonsmall cell
lung cancer (NSCLC), mutations within the EGFR tyrosine
kinase domain, mainly in exons 18, 19 and 21, confer
sensitivity to TKIs [61]. However, such mutations are rare
in SCCHN, ranging from 1% to 7% in caucasian/white and
asian patients, respectively [60, 62, 63]. In a study of 134
SCCHN tumors, direct DNA sequencing could not identify
any mutations [58]. In line with these ﬁndings, we screened
31 tumors for EGFR mutation in exons 18, 19 and 21 and
were able to identify only one patient harboring an EGFR
mutation. Apparently, due to the very low prevalence, EGFR
mutations cannot be used as predictors of response to anti-
EGFR treatment in SCCHN.
Clearly, further studies are needed to fully elucidate the
mechanisms of sensitivity and resistance to cetuximab or
EGFR TKIs. It is possible that other factors that are further
downstream in the EGFR pathway and/or the interplay of
the EGFR pathway with other activated pathways are more
importantthanEGFRaloneinmodulatingresponsestoanti-
EGFR treatments.
Additionally,weassessedMETproteinexpressionbyIHC
and gene copy number by FISH. To our knowledge, this is
the ﬁrst study attempting to correlate MET with response to
concomitant RT with cisplatin and cetuximab. MET protein
expression was noted in 14 of 33 of tumors studied and the
gene was ampliﬁed in 5 of the patients. It appears that, as
in the case of NSCLC [64, 65], MET gene ampliﬁcation is an
infrequenteventinSCCHNaswellandisnotassociatedwith
responses to CCRT.
Interestingly, the present retrospective analysis is one of
a few studies that have investigated a potential association
between ERCC1 protein expression and response to CCRT
in patients with SCCHN. It is noteworthy, that knowledge
regarding the role of ERCC1 in SCCHN is very limited.
Recently, Handra-Luca et al. [66] reported that low ERCC1
protein expression was associated with higher rates of tumor
response (79% versus 56%, P = .04) and lower riskJournal of Oncology 13
of cancer-speciﬁc death (risk ratio 0.42, P = .04) in
patients with SCCHN treated with cisplatin-based induction
chemotherapy. However, this positive association was not
conﬁrmed in a similar study recently conducted by our
group [67] and in the present analysis. The reasons for this
discrepancy, regarding the predictive role of ERCC1, are
not clear. Small sample size, diﬀerences in the treatment
regimens, lack of standardization of the IHC methodology
for assessing ERCC1 protein expression, and diﬀerences in
patient characteristics, stage and tumor location maybe a
few, but certainly not the only factors responsible for the
conﬂicting results.
An important ﬁnding of the present retrospective analy-
sis was that high MMP9 mRNA expression, assessed by kRT-
PCR, was signiﬁcantly associated with objective response.
Positive correlations have been observed between MMP9
mRNA expression levels and metastatic spread of SCCHN
tumors [68]. Overexpression by MMP9 may in part be
regulated via nuclear factor kappa B (NF-kB) [69]. In
addition,inﬂammatoryprocessesinducedbyHPVinfections
could activate MMPs, which would in turn liberate EGFR
ligands from the extracellular matrix, thereby promoting
HNSCC tumor progression through increased EGFR sig-
nalling. It appears therefore, that MMP9 positive tumors
could be particularly sensitive to EGFR inhibition. This
notion is in complete agreement with our ﬁnding that high
MMP9 mRNA expression is signiﬁcantly associated with
objective response to cetuximab containing chemotherapy.
However, further analysis is needed in noncetuximab treated
SCCHN patients, to evaluate whether MMP9 might be
a “poor prognosis marker” turned onto an “improved
response marker” by the addition of cetuximab to RT or
CCRT.
Regarding four commonly studied polymorphic sites in
ERCC1, ERCC2/XPD, and XRCC1, it was interesting to
identifydiscordanttumortissue/peripheralbloodgenotypes.
This may be worthy considering when assessing poly-
morphisms as prognostic/predictive markers in oncology,
since most such available data, including polymorphisms
in excision repair genes, derive from determinations in
peripheral blood (germline) DNA [28, 45, 70]. As indicated
by the diminished presence of one allele with real time PCR,
discordant genotypes in 3 out of 4 cases might correspond to
loss of heterozygosity (LOH) of the corresponding alleles in
the tumor. LOH can be inferred upon SNP-genotyping [71].
This ﬁnding needs further validation, while its biological
impact, if any, is presently unknown, since LOH in ERCC1
and ERCC2/XPD has not been studied in SCCHN. LOH
d o e sn o ts e e mt ob eac o m m o no rm a j o re v e n ti nc o l o r e c t a l
carcinogenesis [72]. Nevertheless, other than previously
reported [28], we did not observe an association between
tumor excision repair gene polymorphisms and patient
outcome, possibly due to the small sample size, while the
investigated polymorphism in ERCC1 was not related to the
corresponding mRNA and protein expression.
Importantly this is the ﬁrst report on the sensitivity
of HPV-associated SCCHN to cetuximab-containing CCRT.
There is a large body of molecular evidence suggesting that
HPV (mainly HPV-16 and HPV-18) plays an important role
in the pathogenesis of SCCHN and particularly of oropha-
ryngealtumors[73, 74]. HPV-16 is the most prevalent geno-
type in SCCHN, accounting for more than 90% of positive
cases [75]. We assessed the presence of HPV by PCR, since
this detection method is probably more sensitive than other
methods, such as in situ hybridization [76]. The frequency of
the presence of HPV, predominantly the HPV-16 genotype,
in Greek patients with oropharyngeal or laryngeal cancer
was 43% and 40%, respectively [77, 78]. Finally there are
several lines of evidence suggesting that, HPV-associated
SCCHN has a better prognosis than SCCHN in HPV-
negative patients, possibly due to enhanced radio-sensitivity
or the absence of ﬁeld cancerization [79]. These data are
in complete accordance with the ﬁndings of our study, in
which exclusively HPV-16 DNA was detected in 6 (20%)
of our patients. Notably, 4 of these patients were evaluable
for response and all of them demonstrated a CR after the
completion of CCRT. The observed high responsiveness of
theHPV-positivepatientsmightpossiblybeduetoactivation
of MMP9. All 4 of the above patients exhibiting a CR had
high MMP9 mRNA expression. Activation of MMP9 could
liberate EGFR ligands from the extracellular matrix, thereby
promoting HNSCC tumor progression through increased
EGFR signalling. MMP9 positive tumors could therefore be,
as discussed earlier, particularly sensitive to EGFR inhibition
with cetuximab.
The p16 overexpression reported here was not associated
with presence of HPV-16, in contrast to previous studies
[80, 81]. As previously shown, p16 overexpression is not
limited to HPV-16 positive cases [82], since a small number
of cases with HPV negative genotype showed very high p16
expression. Furthermore, the ﬁnding of p16 overexpression
in HPV-16 negative tumors may be the result of oncogene-
driven cellular senescence or infection with other viruses
that down-regulate retinoblastoma protein expression [38].
The above combined with the small number of positive
cases could explain the lack of association between p16
and HPV-16 positivity reported in our study. However,
other contributing factors, such as diﬀerences in antibody
speciﬁcity and limitations of the immunohistochemical and
PCR assays cannot be excluded.
As shown in patients with NSCLC, in colorectal or
pancreatic cancer patients treated with anti-EGFR targeted
treatments reviewed in [83], there is a subgroup of patients
that is particularly beneﬁted from such treatments, that is,
those who develop the typical acne-like or maculopapular
rash [57]. In the present analysis, rash of any grade was not
found to be associated with response to CCRT. Likewise,
lack of a correlation between the development of rash and
response to cetuximab was reported in two other studies
in patients with recurrent/metastatic SCCHN [84, 85].
However, in both of these studies, rash was a predictor for
survival and in one of them [84] for time to progression
(TTP), as well. Whether rash will be found to be signiﬁcantly
correlated with TTP or survival remains to be seen with
longer followup. Notably, none of our patients discontinued
CCRT due to severe RT-induced dermatitis, which has
occasionally been reported in patients with SCCHN treated
with RT concomitantly with cetuximab [86]. Nevertheless,14 Journal of Oncology
intensive medical treatment should be oﬀered to these
patients by experienced dermatologists, since in several cases
there is a considerable risk for secondary skin infections.
In conclusion, it appears from the present retrospective
analysis that, CCRT is feasible in patients with locally
advanced SCCHN. However, extremely close monitoring is
required for patients with serious co-morbidities, during
CCRT and the 3-month posttreatment period, because such
patients are at high-risk for dying from nontreatment related
causes. The status of all the genes evaluated in this analysis,
except MMP9, was not of predictive value to CCRT. High
MMP9 mRNA expression, assessed by kRT-PCR, was found
to be signiﬁcantly associated with objective response. It
appears that MMP9 might be of predictive value in SCCHN
patients treated with cetuximab. However, it has to be kept
in mind that, given the retrospective nature of the present
analysis and the relatively small number patients, a selection
bias cannot be excluded. Therefore, our ﬁndings should by
nomeansbeconsideredasdeﬁnitive,butratherashypothesis
generating for future prospective trials.
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